Research programme: adult stem cell therapies - Aegera

Drug Profile

Research programme: adult stem cell therapies - Aegera

Alternative Names: Adult stem cell therapies research programme - Aegera

Latest Information Update: 02 Jun 2011

Price : $50

At a glance

  • Originator Aegera Therapeutics; The Hospital for Sick Children
  • Developer Aegera Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Heart failure; Neurological disorders; Pancreatic disorders

Most Recent Events

  • 02 Nov 2004 Aegera Therapeutics and The Hospital for Sick Children have entered into an agreement to combine their intellectual portfolios regarding the development of skin-derived precursors in Canada
  • 07 Nov 2002 Early research in Pancreatic disorders in USA (unspecified route)
  • 07 Nov 2002 Early research in Neurological disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top